About blinatumomab
Bispecific CD19-directed CD3 T-cell engager
Used for
- Treats certain types of B-cell acute lymphoblastic leukemia (ALL), including relapsed or refractory disease.
- May be used for some adults with newly diagnosed Philadelphia chromosome-negative B-cell precursor ALL.
Usual adult dose
Usually given by continuous intravenous infusion in treatment cycles. Dose depends on disease setting, body weight, and treatment phase.
Usual dose in children
Used in children; continuous intravenous infusion in cycles. Dose depends on body weight, disease setting, and treatment phase.
Common side effects
- Fever, headache, nausea, and fatigue
- Low blood cell counts or infections
- Cytokine release syndrome
- Neurologic problems, including confusion or seizures
Important warnings
- Can cause life-threatening cytokine release syndrome and neurologic toxicity.
- Serious infections and low blood counts may occur.
- Treatment requires close monitoring and specialized infusion procedures.
- Tumor lysis syndrome can occur, especially early in treatment.
Pregnancy
May harm an unborn baby. Pregnancy status is assessed before treatment; effective contraception is generally needed during treatment and for two days afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for two days after the last dose.
Interactions
- Live vaccines should be avoided during treatment and until immune recovery.
- Other medicines that affect the immune system may increase infection or other risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.